Board logo

标题: [绝望] 我手中的一个股票, 等上几百年了, 今天好像要开花了 [打印本页]

作者: aimei    时间: 2013-4-9 13:22     标题: 我手中的一个股票, 等上几百年了, 今天好像要开花了

本帖隐藏的内容需要回复才可以浏览

好激动
作者: freesia    时间: 2013-4-9 13:28

几百年,哈哈
作者: 秂忢空    时间: 2013-4-9 13:29

猜测
作者: 秂忢空    时间: 2013-4-9 13:30

跑了?
作者: aimei    时间: 2013-4-9 13:31

target 3.5

作者: 秂忢空    时间: 2013-4-9 13:33


作者: aimei    时间: 2013-4-9 13:44

回复 4# 秂忢空
not yet
will close half today
wnna get rid of laxi
作者: xiaomanpan    时间: 2013-4-9 13:50

哪个?我手里的垃圾。
作者: aimei    时间: 2013-4-9 14:10

看到 6000 股 在买
怎么办那?
作者: not4weak    时间: 2013-4-9 14:23

回复 9# aimei

In our own experience and observation, extending over 50 years, we have not known a single person who has consistently or lastingly made $ by thus "following the market". We don't hesite to declare that this approach is as fallacious as it it popular.
作者: aimei    时间: 2013-4-9 14:25

回复 10# not4weak
卖了吧
是这个意思吧

作者: aimei    时间: 2013-4-9 14:44

点小二
上酒来
我把你感冒治好了
今天免费就餐

作者: MrBig    时间: 2013-4-9 15:15


作者: aimei    时间: 2013-4-9 17:17

Wedbush analyst Gregory Wade issued a positive report last week on Novavax rating the shares as an "Outperform" with a $4 price target.
The company recently announced top-line data from the Phase II dose-ranging clinical trial of its respiratory syncytial virus that met successful end points.
Vaccine makers are coming into positive focus on the latest bird flu in China. The industry could continue to see a positive impact if the situation gets worse.
Novavax is a clinical-stage biopharmaceutical company that focuses on developing recombinant vaccines for infectious diseases using its virus-like particles (VLP) and recombinant nanoparticle vaccine technology.

6 additional reasons NVAX still could have more upside from $2.40 a share:

Insiders have not sold a share since June 2011. In numerous and frequent purchases since then, myriad insiders have purchased more than $1.5mm in new shares.
M&A activity is on track for its highest pace in years. Given Novavax's interesting niche/products and small market capitalization (just over $300mm after subtracting cash); it could make a logical acquisition for a larger biotech or pharma player trying to get into the vaccine space.
The six analysts that cover the stock have a median price target of $4 a share on NVAX with a mean price target of just over $4.40.
Analysts expect the company's revenues to ramp up more than 50% in FY2014 on the introduction of new vaccines. Sales growth is expected to be north of 15% this fiscal year.
The company has over $40mm in net cash on its balance sheet, which is over two years of funding at its current burn rate.
After consolidating earlier in the year, the stock has been on the move since crossing over its 200 day moving average and is ready to break through its highs of two years ago . The stock reached $6 a share in 2009.
作者: aimei    时间: 2013-4-9 17:17



作者: wsjboy    时间: 2013-4-9 20:26


作者: mppp    时间: 2013-4-9 20:58


作者: seafood    时间: 2013-4-9 22:23

回复 1# aimei

激动阿
作者: aimei    时间: 2013-4-9 22:25

回复 18# seafood

希望赶快放烟花亚

作者: aimei    时间: 2013-4-10 12:25

[fly]烟花来了[/fly]
作者: aimei    时间: 2013-4-10 12:26

在这里接受鲜花和鼓励
谢谢





欢迎光临 华人论坛 (http://169.62.244.154/forum/) Powered by Discuz! 7.2